The role and efficacy of Neratinib

Neratinib (Neratinib) is an oral, irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor of HER1, HER2 and HER4. In the pivotal ExteNET trial in women with early-stage HER2-positive breast cancer who completed adjuvant trastuzumab therapy, 12 months of neratinib treatment significantly reduced the risk of invasive disease recurrence or death compared with placebo at 2 and 5 years after randomization.

Subgroup analysis showed that patients with hormone receptor (HRc)-positive disease benefited more from neratinib treatment than patients with HRc-negative disease, and patients who started neratinib within 1 year after completing trastuzumab had better prognosis than patients who started treatment 1-2 years after trastuzumab. As with other tyrosine kinase inhibitors, diarrhea that can be controlled with antidiarrheal prevention and/or dose adjustment is the most common treatment-emergent adverse event of any grade or grade ≥3 with neratinib. Neratinib offers a valuable option to reduce the risk of relapse and has been included in ESMO patient guidelines.

NeratinibThe original drug is marketed in China as neratinib maleate tablets and is covered by Class B medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of each box of 40mg*180 tablets may be around 7,000 yuan. Generic drugs of neratinib are also sold overseas. The drug ingredients are basically the same as those of the original drug. The price of 40mg*180 tablets produced by Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to the exchange rate). For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.